Fangming Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fangming Liu has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Xiangdong Wang
Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital Fudan University Shanghai Medical College Shanghai China
3 shared publications Charles A. Powell
Division of Pulmonary, Critical Care and Sleep Medicine Icahn School of Medicine at Mount Sinai New York New York USA
1 shared publication- Cheng-Chao Ruan
Shanghai Key Laboratory of Bioactive Small Molecules, Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China
1 shared publication Chengshui Chen
The Quzhou Affiliated Hospital of Wenzhou Medical University Quzhou People's Hospital Quzhou China
1 shared publication- Claudio Spada
Healthcare Accountability Lab, University of Milan, Milan, Italy
1 shared publication Dongli Song
Zhongshan Hospital Institute of Clinical Science Zhongshan Hospital, Shanghai Medical College Fudan University Shanghai China
1 shared publication
Latest Publications
- Open Access
- 27 February 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (7)
Immunometabolite L-2-HG promotes epigenetic modification of exhausted T cells and improves antitumor immunity
This study aimed to explore the potential correlation between the metabolic intermediate L-2-hydroxyglutarate (L-2-HG) and T cell exhaustion, as well as the underlying mechanisms involved. In this study, we investigated the presence of exhausted T (Tex) cells in patients under certain conditions: HIV infection, chronic leukemia, and hepatocellular carcinoma. To gain insights into the epigenetic signatures and transcriptome changes in Tex cells, we employed a combination of RNA-seq and ATAC-seq analyses. To evaluate the impact of L-2-HG on mitochondrial function, differentiation, and antitumor capacity of Tex cells, we utilized in vitro cell culture experiments and animal tumor models. We observed mitochondrial depolarization and metabolic dysfunction in Tex cells, accompanied by a significant reduction in L-2-HG levels. Moreover, altered epigenetic characteristics were observed in Tex cells, including a substantial increase in H3K27me3 abundance. Culturing Tex cells with L-2-HG demonstrated improved mitochondrial metabolism, reduced H3K27me3 abundance, and enhanced memory T cell differentiation. In a mouse melanoma tumor model, L-2-HG–treated CD8 + T cells for adoptive therapy led to significantly reduced tumor volume and significantly enhanced effector function of T cells. The study revealed that L-2-HG acted as an immune metabolite through epigenetic modifications of Tex cells.
- 27 February 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (7)
Open AccessImmunometabolite L-2-HG promotes epigenetic modification of exhausted T cells and improves antitumor immunity
This study aimed to explore the potential correlation between the metabolic intermediate L-2-hydroxyglutarate (L-2-HG) and T cell exhaustion, as well as the underlying mechanisms involved. In this study, we investigated the presence of exhausted T (Tex) cells in patients under certain conditions: HIV infection, chronic leukemia, and hepatocellular carcinoma. To gain insights into the epigenetic signatures and transcriptome changes in Tex cells, we employed a combination of RNA-seq and ATAC-seq analyses. To evaluate the impact of L-2-HG on mitochondrial function, differentiation, and antitumor capacity of Tex cells, we utilized in vitro cell culture experiments and animal tumor models. We observed mitochondrial depolarization and metabolic dysfunction in Tex cells, accompanied by a significant reduction in L-2-HG levels. Moreover, altered epigenetic characteristics were observed in Tex cells, including a substantial increase in H3K27me3 abundance. Culturing Tex cells with L-2-HG demonstrated improved mitochondrial metabolism, reduced H3K27me3 abundance, and enhanced memory T cell differentiation. In a mouse melanoma tumor model, L-2-HG–treated CD8 + T cells for adoptive therapy led to significantly reduced tumor volume and significantly enhanced effector function of T cells. The study revealed that L-2-HG acted as an immune metabolite through epigenetic modifications of Tex cells.
- Open Access
- 12 February 2024
- Published by Wiley in Clinical and Translational Discovery
- Vol. 4 (1)
Single‐cell RNA sequencing reveals telocytes subsets of human lung
Background: Telocyte (TC) is a recently defined renewed cell and its dominant intercommunication with other cells displays multiple functions in tissue homeostasis and diseases. Alveolar epithelial cells and immune cells were in the lung cancer heterogeneity, progression, and metastasis, and further associated with antitumor therapeutic strategies. However, few studies focus on the roles of TCs in lung cancer.Methods: In this article, we used the public scRNA‐Seq data (including healthy control, chronic obstructive pulmonary disease, non–small cell lung cancer, lymph node metastases from non–small cell lung cancer, and systemic sclerosis–associated interstitial lung disease patients) to analyze the cellular dynamics in human lung and distinct types of TCs and their communication networks with the variety of cell types.Results: Six subclusters of TCs were identified by expression of specific biological function markers, which demonstrated the diversity of TCs subsets in lung tissue. Further results showed TCs had communication with epithelial cells or immune cells subsets by the ligand–receptor interaction, including TIMP metallopeptidase inhibitor 1CD63, fibulin 1integrin subunit beta 1, vimentinCD44, macrophage migration inhibitory factorCD74, and amyloid beta precursor proteinCD74. Ligand–receptor interaction heterogeneity was revealed in lung tissue of healthy or diseases. Enhanced specific signals in ligandreceptor interaction were revealed, including integrin beta 1 and CD44 were appraised in the communication of TCs with epithelial cells, NK cells, NKT cells, CD4+ exhausted T cells, CD4+ memory/effector T cells, CD4+ naïve T cells, CD8+ exhausted T cells, CD8+ memory/effector T cells, and CD8+ naïve T cells. CD63, a marker identified in TCs exosomes was emphasized in our current analysis which is closely related to communication of TCs with other cell types.Conclusion: These results will provide us with new insight into the mechanisms of TCs‐dominated communication and promise therapy of TC exosomes in lung diseases.
- 12 February 2024
- Published by Wiley in Clinical and Translational Discovery
- Vol. 4 (1)
Open AccessSingle‐cell RNA sequencing reveals telocytes subsets of human lung
Background: Telocyte (TC) is a recently defined renewed cell and its dominant intercommunication with other cells displays multiple functions in tissue homeostasis and diseases. Alveolar epithelial cells and immune cells were in the lung cancer heterogeneity, progression, and metastasis, and further associated with antitumor therapeutic strategies. However, few studies focus on the roles of TCs in lung cancer.Methods: In this article, we used the public scRNA‐Seq data (including healthy control, chronic obstructive pulmonary disease, non–small cell lung cancer, lymph node metastases from non–small cell lung cancer, and systemic sclerosis–associated interstitial lung disease patients) to analyze the cellular dynamics in human lung and distinct types of TCs and their communication networks with the variety of cell types.Results: Six subclusters of TCs were identified by expression of specific biological function markers, which demonstrated the diversity of TCs subsets in lung tissue. Further results showed TCs had communication with epithelial cells or immune cells subsets by the ligand–receptor interaction, including TIMP metallopeptidase inhibitor 1CD63, fibulin 1integrin subunit beta 1, vimentinCD44, macrophage migration inhibitory factorCD74, and amyloid beta precursor proteinCD74. Ligand–receptor interaction heterogeneity was revealed in lung tissue of healthy or diseases. Enhanced specific signals in ligandreceptor interaction were revealed, including integrin beta 1 and CD44 were appraised in the communication of TCs with epithelial cells, NK cells, NKT cells, CD4+ exhausted T cells, CD4+ memory/effector T cells, CD4+ naïve T cells, CD8+ exhausted T cells, CD8+ memory/effector T cells, and CD8+ naïve T cells. CD63, a marker identified in TCs exosomes was emphasized in our current analysis which is closely related to communication of TCs with other cell types.Conclusion: These results will provide us with new insight into the mechanisms of TCs‐dominated communication and promise therapy of TC exosomes in lung diseases.
- Open Access
- 20 January 2023
- Published by Wiley in Clinical and Translational Discovery
- Vol. 3 (1)
Initiative of clinical single‐cell biomedicine in clinical and translational medicine
Background: With rapid developments of single‐cell sequencing and multi/trans‐omics, clinical single‐cell biomedicine is a new and emergent discipline to integrate single‐cell molecular and clinical phenomes and uncover new disease‐specific diagnosis and therapy.Aims: The journal of Clinical and Translational Medicine (CTM) launches the first CTM initiative of Clinical Single‐Cell Biomedicine (cscBioMed) to promote the discovery and development of single‐cell‐based biology and medicine, speed the translation from single‐cell biology into clinical application, and improve early diagnosis and therapy for human diseases.Materials & Methods: The cscBioMed initiative is speeding translational processes from circulating single‐cell RNA sequencing (scRNA‐seq) into routine measures in clinical biochemistry of hematology, from spatial transcriptomics into single‐cell pathology, from single‐cell‐based biomarkers and targets into clinical diagnostics and target drugs.Conclusion: With a clear goal, we expect that cscBioMed will benefit the human health by establishing a clinical single‐cell dynamic monitoring and early predicting system and by improving diagnosis and treatment.
- 20 January 2023
- Published by Wiley in Clinical and Translational Discovery
- Vol. 3 (1)
Open AccessInitiative of clinical single‐cell biomedicine in clinical and translational medicine
Background: With rapid developments of single‐cell sequencing and multi/trans‐omics, clinical single‐cell biomedicine is a new and emergent discipline to integrate single‐cell molecular and clinical phenomes and uncover new disease‐specific diagnosis and therapy.Aims: The journal of Clinical and Translational Medicine (CTM) launches the first CTM initiative of Clinical Single‐Cell Biomedicine (cscBioMed) to promote the discovery and development of single‐cell‐based biology and medicine, speed the translation from single‐cell biology into clinical application, and improve early diagnosis and therapy for human diseases.Materials & Methods: The cscBioMed initiative is speeding translational processes from circulating single‐cell RNA sequencing (scRNA‐seq) into routine measures in clinical biochemistry of hematology, from spatial transcriptomics into single‐cell pathology, from single‐cell‐based biomarkers and targets into clinical diagnostics and target drugs.Conclusion: With a clear goal, we expect that cscBioMed will benefit the human health by establishing a clinical single‐cell dynamic monitoring and early predicting system and by improving diagnosis and treatment.
- Open Access
- 20 February 2022
- Published by Wiley in Clinical and Translational Discovery
- Vol. 2 (1) , e24
Regulation of Epstein–Barr virus‐induced molecule 2 in immune responses
Epstein–Barr virus‐induced molecule 2 (EBI2) is well known as a chemotactic receptor for B cells, T cells, dendritic cells (DCs) and other various cell populations. With the deepening of research, it is thought that EBI2 may also play a key role in functional responses, such as immune regulation, differentiation and tissue homeostasis. An abnormal expression of EBI2 has been considered to be associated with diseases, including inflammation and chronic diseases. In this review, we expounded the molecular mechanism of activation of EBI2 stimulated by its most effective agonist, 7α, 25‐OHC, and discussed typical research findings on EBI2 in immune control in recent decades. In addition, diseases caused by unusual EBI2 regulation have also been discussed, especially chronic obstructive pulmonary disease (COPD). In conclusion, EBI2 has been potentially regarded as a therapeutic target for chronic inflammation.
- 20 February 2022
- Published by Wiley in Clinical and Translational Discovery
- Vol. 2 (1) , e24
Open AccessRegulation of Epstein–Barr virus‐induced molecule 2 in immune responses
Epstein–Barr virus‐induced molecule 2 (EBI2) is well known as a chemotactic receptor for B cells, T cells, dendritic cells (DCs) and other various cell populations. With the deepening of research, it is thought that EBI2 may also play a key role in functional responses, such as immune regulation, differentiation and tissue homeostasis. An abnormal expression of EBI2 has been considered to be associated with diseases, including inflammation and chronic diseases. In this review, we expounded the molecular mechanism of activation of EBI2 stimulated by its most effective agonist, 7α, 25‐OHC, and discussed typical research findings on EBI2 in immune control in recent decades. In addition, diseases caused by unusual EBI2 regulation have also been discussed, especially chronic obstructive pulmonary disease (COPD). In conclusion, EBI2 has been potentially regarded as a therapeutic target for chronic inflammation.
- Open Access
- 1 October 2021
- Published by Wiley in Clinical and Translational Discovery
- Vol. 1 (1) , e17
Disorder of three‐dimensional chromosome structure plays a role in carcinogenesis
The three‐dimensional structure of chromatin is an essential part of gene expression and regulation. Modules far apart in the one‐dimensional DNA sequence can be close to each other in 3D and activated by spatially folding. Normal gene activation requires such long‐distance interactions. However, the formation of faulty structures of chromosomes can lead to disorders of genetic function, such as cancer. With the development of three‐dimensional (3D) capture techniques, chromatin disorders associated with cancer are gaining attention. In this review, we combined several studies on the 3D genome, regulation and progress of gene expression and involvement of 3D chromatin variation in the development of cancer. We will discuss the possibility and potential value of using the 3D genome as a new target in the clinical diagnosis and treatment of cancer. In a word, high‐order chromatin architecture can provide a new perspective for the study of oncogenic alterations.
- 1 October 2021
- Published by Wiley in Clinical and Translational Discovery
- Vol. 1 (1) , e17
Open AccessDisorder of three‐dimensional chromosome structure plays a role in carcinogenesis
The three‐dimensional structure of chromatin is an essential part of gene expression and regulation. Modules far apart in the one‐dimensional DNA sequence can be close to each other in 3D and activated by spatially folding. Normal gene activation requires such long‐distance interactions. However, the formation of faulty structures of chromosomes can lead to disorders of genetic function, such as cancer. With the development of three‐dimensional (3D) capture techniques, chromatin disorders associated with cancer are gaining attention. In this review, we combined several studies on the 3D genome, regulation and progress of gene expression and involvement of 3D chromatin variation in the development of cancer. We will discuss the possibility and potential value of using the 3D genome as a new target in the clinical diagnosis and treatment of cancer. In a word, high‐order chromatin architecture can provide a new perspective for the study of oncogenic alterations.